Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05011513 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1,440
- Enrollment target
NCT05011513: Clinical Trial Phase 2 study, sponsored by Pfizer.
NCT05011513 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 1,440 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (983% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05011513, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1,440 participants
- Enrollment target
Study Summary
The primary hypothesis to be tested is whether or not there is a difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo.
Primary Outcome
Sustained alleviation of targeted COVID-19 signs/symptoms was defined as the event occurring on the first 4 consecutive days when all symptoms scored as moderate or severe at the time of enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. Missing severity at baseline was considered as mild. Time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28, was calculated as time (days) from start of stud
Interventions
- DRUG Placebo
- DRUG Ritonavir
- DRUG PF-07321332
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,440 participants |
| Start Date | 2021-08-25 |
| Est. Completion | 2022-07-25 |
| Phase | Phase 2 |
Why NCT05011513 stopped before completion
NCT05011513 is an interventional study that assigns participants to a tested intervention. Its 1,440 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (983% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05011513 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05011513 about?
NCT05011513 is a clinical study titled "Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).". The primary hypothesis to be tested is whether or not there is a difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo.
What is the current status of trial NCT05011513?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1,440 participants. The study started on 2021-08-25. Estimated completion is 2022-07-25.
What interventions are being tested in trial NCT05011513?
The interventions under investigation include: Placebo (DRUG), Ritonavir (DRUG), PF-07321332 (DRUG).
Who is sponsoring clinical trial NCT05011513?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05011513's enrollment target sits among peer trials
1,440 12th of 2000 higher than 1,989 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04754022 · 1,440 participants · NA
Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery
- NCT04989790 · 1,440 participants · NA
Clinical Effectiveness of the "PICU Up!" Multifaceted Early Mobility Intervention for Critically Ill Children
- NCT06122246 · 1,440 participants · NA
PRESSURE CHECK: Find Your Path to Better Health
- NCT06324318 · 1,440 participants · Phase 2
Parenting in 2 Worlds Multisite Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI